Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to ...

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...